We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 213

Decisions in leave to appeal to the Supreme Court

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 18 2013

The Supreme Court is releasing their judgment for two leave decisions this Thursday. The first, Gilead Science Canada Inc. v. Minister of Health

The Court of Appeal sends s.8 case back to trial judge for redetermination

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 26 2012

The Federal Court of Appeal (FCA) has granted Apotex’ appeal and sent a case considering s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations) back to the Trial Judge for redetermination

Court finds allegations in NOA to be unjustified, however dismisses application for prohibition on basis of mootness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 18 2010

In this proceeding under the NOC Regulations, the Court found all of Apotex’ allegations to be unjustified

Final amount for section 8 damages determined

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 12 2012

The Court had previously provided a judgment, resolving a number of matters in dispute between the parties with respect to the amount of compensation to be paid pursuant to s. 8 of the NOC Regulations (summary here

Court of Appeal refuses to reinstate patent when fees paid by someone other than the authorized agent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 24 2011

This is an appeal of a judgment dismissing an application for a judicial review of a decision of the Commissioner of Patents

Pfizer Canada Inc. v. Novopharm, The Minister of Health, Northwestern University and the Board of Regents for the University of Oklahoma

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 5 2010

In a proceeding pursuant to the Patented Medicines (Notice of Compliance) Regulations, Novopharm brought a motion seeking a Protective Order that allowed the designation of Novopharm's Notice of Allegation (NOA) as confidential

Only authorized correspondent can pay maintenance fees for application

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 14 2011

The Judge found that the acceptance of maintenance fees paid within the grace period by someone other than the authorized correspondent reinstated a lapsed patent application, but the subsequent reimbursement of those fees nullified the reinstatement

Court declares drug eligible for listing on the register of innovative drugs

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 13 2012

In this case, Celgene judicially reviewed a decision of the Minister of Health not to list their drug THALOMID thalidomide on the Register of Innovative Drugs (the Register

Leave denied by Supreme Court of Canada in pharmaceutical case

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 12 2011

Leave by the Supreme Court of Canada (SCC) was denied in respect of the decision by the Federal Court of Appeal

Other IP industry news of note

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 25 2010

The amendments to the Federal Court Rules regarding expert witnesses have been published into law (starting at pg 1547